Preoperative Pyuria as a Predictor of False‐Positive Rates in the Photodynamic Diagnosis of Nonmuscle‐Invasive Bladder Cancer Using Oral 5‐Aminolevulinic Acid

Documenti analoghi

• Successful Management of Tumor Lysis Syndrome Following Enfortumab Vedotin Plus Pembrolizumab Therapy in Metastatic Urothelial Carcinoma: A Case Report
  di: Daigo Takemori, et al.
  Pubblicazione: (2025)
• Comment on “Association Between Preoperative 5‐Aminolevulinic Acid Administration Timing and Perioperative Hypotension”
  di: Shinkuro Yamamoto, et al.
  Pubblicazione: (2026)
• Transcutaneous Imiquimod Combined With Anti‐Programmed Cell Death‐1 Monoclonal Antibody Extends the Survival of Mice Bearing Renal Cell Carcinoma
  di: Takashi Karashima, et al.
  Pubblicazione: (2025)
• Photodynamic Therapeutic Effect during 5‐Aminolevulinic Acid‐Mediated Photodynamic Diagnosis‐Assisted Transurethral Resection of Bladder Tumors
  di: Nobutaka Nishimura, et al.
  Pubblicazione: (2024)
• Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5‐Aminolevulinic Acid–Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial
  di: Rikiya Taoka, et al.
  Pubblicazione: (2025)